Novartis: plans blood cancer drug trial to fight coronavirus
(CercleFinance.com) - Novartis plans to start trials on its blood cancer drug Jakavi to treat patients with severe COVID-19 symptoms, the Swiss drugmaker said on Friday.
The company said it will initiate a Phase III clinical trial in collaboration with US partner Incyte to evaluate the use of Jakavi for treatment of severe immune overreaction, that can lead to life-threatening respiratory complications in coronavirus patients.
Novartis said that this decision is based on pre-clinical evidence and preliminary reports from independent studies.
"The potential that Jakavi could lead to faster recovery times for COVID-19 patients with fewer requiring intensive care and mechanical ventilation is encouraging and absolutely merits further investigation", the group said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The company said it will initiate a Phase III clinical trial in collaboration with US partner Incyte to evaluate the use of Jakavi for treatment of severe immune overreaction, that can lead to life-threatening respiratory complications in coronavirus patients.
Novartis said that this decision is based on pre-clinical evidence and preliminary reports from independent studies.
"The potential that Jakavi could lead to faster recovery times for COVID-19 patients with fewer requiring intensive care and mechanical ventilation is encouraging and absolutely merits further investigation", the group said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.